A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304 · clinicaltrials.gov ↗

COMPLETED

Status

11316

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE: Trelegy Ellipta
DEVICE: Stiolto Respimat
DRUG: Furoate/Umeclidinium/Vilanterol
DRUG: Tiotropium Bromide/Olodaterol

Sponsor

Boehringer Ingelheim